Bionomics Ltd’s ADR shares (BNOX) have soared by 177% to 53 cents following a $1 million milestone payment from Carina Biotech for their partnered oncology program, BNC101. This payment, tied to a 2020 license agreement, underscores the potential of BNC101, a monoclonal antibody targeting cancer stem cells. The news also highlights Bionomics’ ongoing research strength and strategic partnerships, including their collaboration with Merck on an Alzheimer’s therapy.